Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

47.44 +1.84 (+4.02%)
Streaming Delayed Price Updated: 3:32 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 722,400
Open 47.23
Bid (Size) 47.37 (500)
Ask (Size) 47.45 (100)
Prev. Close 45.60
Today's Range 45.75 - 48.19
52wk Range 15.86 - 48.03
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Urogen Pharma Q2 Earnings Call Highlights ↗
Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain... 
Via MarketBeat
Topics Earnings
News headline image
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire

Performance

YTD
+108.9%
+108.9%
1 Month
+25.7%
+25.7%
3 Month
+78.4%
+78.4%
6 Month
+131.2%
+131.2%
1 Year
+137.1%
+137.1%

More News

Read More
News headline image
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
From UroGen Pharma Ltd.
Via GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗
Via Chartmill
UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates ↗
Via Chartmill
News headline image
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Via The Motley Fool
News headline image
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
Via The Motley Fool
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
Via The Motley Fool

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 47.44
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 08/07/26 03:32 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 1.71B
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.